- Home
- IMTX vs VINP Comparison
IMTX vs VINP Comparison
Compare IMTX & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- VINP
- Stock Information
- Founded
- IMTX N/A
- VINP 2009
- Country
- IMTX Germany
- VINP Brazil
- Employees
- IMTX N/A
- VINP N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- VINP Investment Managers
- Sector
- IMTX Health Care
- VINP Finance
- Exchange
- IMTX Nasdaq
- VINP Nasdaq
- Market Cap
- IMTX 579.8M
- VINP 593.2M
- IPO Year
- IMTX N/A
- VINP 2021
- Fundamental
- Price
- IMTX $5.61
- VINP $9.66
- Analyst Decision
- IMTX Strong Buy
- VINP Strong Buy
- Analyst Count
- IMTX 4
- VINP 2
- Target Price
- IMTX $14.67
- VINP $13.25
- AVG Volume (30 Days)
- IMTX 754.4K
- VINP 44.9K
- Earning Date
- IMTX 08-12-2025
- VINP 08-06-2025
- Dividend Yield
- IMTX N/A
- VINP 6.52%
- EPS Growth
- IMTX N/A
- VINP N/A
- EPS
- IMTX N/A
- VINP 0.38
- Revenue
- IMTX $155,801,989.00
- VINP $126,696,258.00
- Revenue This Year
- IMTX N/A
- VINP $70.28
- Revenue Next Year
- IMTX $1.92
- VINP $14.37
- P/E Ratio
- IMTX N/A
- VINP $25.37
- Revenue Growth
- IMTX 93.56
- VINP 57.51
- 52 Week Low
- IMTX $3.30
- VINP $8.66
- 52 Week High
- IMTX $13.09
- VINP $11.62
- Technical
- Relative Strength Index (RSI)
- IMTX 51.00
- VINP 50.59
- Support Level
- IMTX $5.90
- VINP $9.25
- Resistance Level
- IMTX $6.38
- VINP $9.99
- Average True Range (ATR)
- IMTX 0.39
- VINP 0.26
- MACD
- IMTX -0.05
- VINP 0.01
- Stochastic Oscillator
- IMTX 16.30
- VINP 55.71
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.